AI NewsGo-to-marketReported
Odaia raises $15M Series C to target doctors for pharma sales teams
Toronto startup Odaia raised $15 million Series C. The product helps pharma reps decide which doctors to call next.

Why it mattersPharma sales reps still cold-call doctors. A ranked call list from an AI platform is a concrete win. Odaia says four of the top 15 global pharmas use it.
A pharmaceutical sales rep calls doctors to talk about a drug. The job is older than the laptop on the desk. Most of the day is still spent deciding who to call next from a fragmented list. A Toronto company that works on that one problem raised $15 million this week.
Odaia announced the round on 12 November 2026 from Toronto. Monograph Capital led the Series C. BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures all returned. A new strategic investor also came in: Publicis Health Media, part of Publicis Groupe. PHM signed a commercial deal at the same time.
What the platform does
Odaia's platform reads data about doctors from many sources. It then predicts which doctor is most likely to have patients ready for a specific drug. A sales rep opens the tool and sees a ranked list of doctors. Each name carries the reason it was picked. The marketing-facing tool does the same work for digital campaigns. Odaia says five AI engines sit under the product, and that it all runs in real time.
The company is based in Toronto at 150 King Street West. It keeps a Boston office at 361 Newbury Street. Philip Poulidis is the CEO and a co-founder. "Pharma has proven that AI works in commercial," he said in the release. "The hard part now is scaling it."
Who is paying for it
Odaia's release says "four of the top 15 global biopharmaceutical organizations" use the platform. The four are not named. BetaKit reported the same figure on 18 November and also did not name them. That is the one named customer figure attached to the round. It is the company's own count.
The Publicis Health Media deal is a sales partnership. PHM becomes Odaia's exclusive agency partner in the United States. The scope covers health, pharma, biotech and wellness. PHM will plug the platform into its own client work. Agencies are the route into the top ten drug companies in the US. This deal is Odaia reaching those buyers without hiring its own US sales team.
What the money is for
The company says it will use the $15 million to grow inside the pharma accounts it already serves. It also plans to keep building the platform. The release names one target market, pharma commercial, and one geography, the United States, through the PHM partnership. The plain read is that Odaia stays in the lane it has. The Series C is money to serve that lane better.
A founder selling AI into a regulated industry can read Odaia's path as one datapoint. The company kept the scope narrow. It stayed in one function, pharma commercial, for seven years. It built partnerships with agencies that already sell into drug companies. It did not try to displace those agencies. That path is slower than a general-purpose agent. It is the path that got Odaia to a US$15 million Series C with a named strategic partner attached.
Source
This item was written by an AI system from the linked source. Reveneau is responsible for what it publishes.
Get AI News in your inbox
New developer tools, model and agent releases, and how teams are actually using them to release software. Short, and only when there is something worth reading.


